Geode Capital Management
PRLD icon

Geode Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Geode Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
302,458
+29,572
+11% +$77.5K ﹤0.01% 3345
2025
Q4 		$792K Buy
272,886
+55,318
+25% +$93.3K ﹤0.01% 3446
2025
Q3 		$313K Hold
217,568
– – ﹤0.01% 3782
2025
Q2 		$176K Sell
217,568
-187,387
-46% -$162K ﹤0.01% 3914
2025
Q1 		$311K Buy
404,955
+2,619
+0.7% +$2.44K ﹤0.01% 3708
2024
Q4 		$513K Buy
402,336
+10,620
+3% +$14.1K ﹤0.01% 3584
2024
Q3 		$811K Buy
391,716
+29,765
+8% +$138K ﹤0.01% 3427
2024
Q2 		$1.38M Buy
361,951
+319
+0.1% +$1.3K ﹤0.01% 3202
2024
Q1 		$1.71M Buy
361,632
+12,265
+4% +$47.7K ﹤0.01% 3175
2023
Q4 		$1.49M Buy
349,367
+18,267
+6% +$55.6K ﹤0.01% 3194
2023
Q3 		$1.02M Buy
331,100
+88,806
+37% +$333K ﹤0.01% 3307
2023
Q2 		$1.09M Buy
242,294
+96,390
+66% +$576K ﹤0.01% 3317
2023
Q1 		$832K Buy
145,904
+1,227
+0.8% +$7.48K ﹤0.01% 3427
2022
Q4 		$873K Sell
144,677
-8,414
-5% -$53.9K ﹤0.01% 3408
2022
Q3 		$1.01M Buy
153,091
+17,450
+13% +$118K ﹤0.01% 3380
2022
Q2 		$708K Sell
135,641
-71,935
-35% -$366K ﹤0.01% 3571
2022
Q1 		$1.43M Sell
207,576
-5,060
-2% -$46.3K ﹤0.01% 3434
2021
Q4 		$2.65M Sell
212,636
-36,536
-15% -$594K ﹤0.01% 3236
2021
Q3 		$7.79M Buy
249,172
+25,920
+12% +$839K ﹤0.01% 2646
2021
Q2 		$6.39M Buy
223,252
+24,061
+12% +$857K ﹤0.01% 2755
2021
Q1 		$8.63M Buy
199,191
+7,563
+4% +$502K ﹤0.01% 2453
2020
Q4 		$13.7M Buy
+191,628
New +$9.53M ﹤0.01% 1948

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management's PRLD Position: Q1 2026 in Review

Geode Capital Management increased its Prelude Therapeutics (PRLD) stake by 11% in Q1 2026, buying an estimated $77.5K and bringing the position to 302,458 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

Geode Capital Management first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $13.7M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Geode Capital Management held 302,458 shares of Prelude Therapeutics worth $1.03M as of Q1 2026.
  • Geode Capital Management bought 29,572 Prelude Therapeutics shares in Q1 2026, an estimated $77.5K.
  • Prelude Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3345 holding.
  • Geode Capital Management first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Geode Capital Management's Prelude Therapeutics position peaked at $13.7M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.